The approvals of two groundbreaking vaccines in the last month is encouraging news. Vaccines have long been undervalued because they haven't been as profitable as other pharmaceuticals. So it's good to see them getting deserved attention that goes beyond fears of flu outbreaks.
Several recent approvals highlight progress in developing both prophylactic and therapeutic vaccines.
The transdermal delivery of biologics-as well as of conventional drugs-is growing in popularity because the technique offers numerous advantages.
Disposables can be used for media preparation, clarification, filling in downstream processes . . .
Certain areas of the vaccine market appear to be in vogue again, revitalized by blockbusters such as Prevnar, the pneumococcal pneumonia vaccine that reaped $1.5 billion in sales last year, and the human papilloma virus vaccines, which are projected to reach $4 billion per year.
The federal government plans to spend $3.3 billion on bird flu initiatives, about half of that on a vaccine.
Human infections with avian flu strain H5N1 are occurring in a number of southeast Asian countries that have experienced large outbreaks of avian influenza. How great a risk to the human population is posed by this virus, and what steps can be taken to minimize its impact? Preventive vaccines have great potential to avert the spread of avian flu and other infectious diseases. What are the factors affecting the creation of new vaccines, and how can they be optimized to promote public health?
FDA plans to conduct good manufacturing practices (GMP) inspections of flu vaccine manufacturers annually instead of every two years.
Bioterrorism legislation is in the works, but there will be a tough fight to enact added liability protections for manufacturers.
